Clinical trial
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women…
NCT00374322 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00374322 |
|---|---|
| Title | Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer |
| Official title | A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug, Other |
| Interventions | lapatinib, placebo |
| Enrollment | 3,166 |
| Start date | Aug 1, 2006 |
| Primary completion | Sep 1, 2011 |
| Completion | Jul 1, 2013 |
| First posted | Sep 11, 2006 |
| Last update posted | Aug 18, 2014 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Croatia, Czechia, Denmark, France, Germany and 21 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: